Cure My Disease

Don't miss your cure!

 Log in / Sign up

New triple therapy shows promise for aggressive lung cancer

NCT ID NCT04660097

Disease control Sponsor: Henan Cancer Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of two drugs (durvalumab and anlotinib) plus standard chemotherapy as a first treatment for people with extensive-stage small-cell lung cancer, a fast-growing cancer. 34 adults took part. The goal was to see if the combo helps delay cancer growth or shrink tumors. This is not a cure, but aims to control the disease longer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

34 people

The number who actually took part.

Started

May 2021

Finished

Jun 2024

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed primary treatment of ES-SCLC (small cell lung cancer) in male or female patients aged ≥18 and \<75 years. * The ECOG energy status is 0 or 1. * Appropriate hematologic and terminal organ functions. Exclusion Criteria: * Prior to systemic treatment, the patient had a history of chest radiation therapy or planned to undergo intensive chest radiation therapy. * Spinal cord compression not explicitly treated by surgery and/or radiation, or previously diagnosed and treated, with no evidence of clinical stabilization of \>2 weeks prior to randomization. Active brain metastases (stable brain metastases may be admitted after treatment) occurred within one month prior to enrollment. * Uncontrolled or symptomatic hypercalcemia, active tuberculosis, major cardiovascular disease. * A history of autoimmune diseases, idiopathic pulmonary fibrosis, organized pneumonia, HIV positive, active hepatitis B, radiographic findings of tumor infiltration of the large vessels in the chest and significant pulmonary cavitation lesions, a previous history of hypertensive crisis or hypertensive encephalopathy. * History of hemoptysis within 1 month prior to randomization (≥0.5 TSP of bright red blood per episode). * Major surgery within 28 days or needle core biopsy or other minor surgical procedures within 7 days.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCLC, extensive stage are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCLC, extensive stage

Contacts and locations

Locations

  • Henan Tumor Hospital

    Zhengzhou, Henan, 450000, China

  • Sixth People's Hospital of Luoyang

    Luoyang, Henan, 471000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.